IGNE — Igene Biotechnology Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -181.79% | ||
| Return on Equity | n/a | ||
| Operating Margin | -59804.36% | ||
Financial Summary
| Year End 31st Dec | Unit | 2005 | 2006 | 2007 | 2008 | 2009 | 2010E | 2011E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 2.29 | 7.64 | 3.96 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
IGENE Biotechnology, Inc. (Igene) is focused on the research, development, production and commercialization of specialty ingredients for human and animal nutrition. The Company develops, produces and markets specialty biochemical products. It is a supplier of natural astaxanthin, a nutrient in different feed applications and a source of pigment for coloring farmed salmon species. Igene provides research and development services for microbial strain improvement and fermentation process development and scale up from shake flask, to pilot plant, to commercial sized fermentors. It also provides analytical chemistry services for identification and quantization of carotenoids in foods, feeds, and animal tissues, including verification of wild versus farm raised salmonids. Within animal nutrition, the Company focus is to deliver astaxanthin to the fish feed market.
Directors
- Michael Kimelman CHM (76)
- Stephen Hiu PRE (54)
- Thomas Kempner VCH (87)
- Edward Weisberger CFO (51)
- Patrick Monahan VPR (60)
- Sidney Knafel DRC (88)
- Last Annual
- December 31st, 2009
- Last Interim
- September 30th, 2010
- Incorporated
- October 27th, 1981
- Public Since
- July 29th, 1986
- No. of Shareholders
- 250
- No. of Employees
- 18
- Sector
- Chemicals
- Industry
- Basic Materials
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 1,565,404,297
- Address
- 9110 Red Branch Rd, Suite J, COLUMBIA, 21045-2024
- Web
- Phone
- +1 4109972599
- Auditors
- M&K CPAS PLLC
Similar to IGNE
Advanced Container Technologies
Pink Sheets on Nasdaq
Alkane
Pink Sheets on Nasdaq
Angstrom Technologies
Pink Sheets on Nasdaq
Asia Carbon Industries
Pink Sheets on Nasdaq
BioLargo
Pink Sheets on Nasdaq
FAQ
As of Today at 21:14 UTC, shares in Igene Biotechnology are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Igene Biotechnology last closed at $0.00 and the price had moved by over the past 365 days. In terms of relative price strength the Igene Biotechnology share price has underperformed the S&P500 Index by -6.57% over the past year.
There is no consensus recommendation for this security.
Find out moreIgene Biotechnology does not currently pay a dividend.
Igene Biotechnology does not currently pay a dividend.
Igene Biotechnology does not currently pay a dividend.
To buy shares in Igene Biotechnology you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Igene Biotechnology had a market capitalisation of .
Here are the trading details for Igene Biotechnology:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: IGNE
Based on an overall assessment of its quality, value and momentum Igene Biotechnology is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Igene Biotechnology. Over the past six months, its share price has outperformed the S&P500 Index by +3.51%.
As of the last closing price of $0.00, shares in Igene Biotechnology were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Igene Biotechnology PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Igene Biotechnology's management team is headed by:
- Michael Kimelman - CHM
- Stephen Hiu - PRE
- Thomas Kempner - VCH
- Edward Weisberger - CFO
- Patrick Monahan - VPR
- Sidney Knafel - DRC